Open Access. Powered by Scholars. Published by Universities.®

Life Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 4 of 4

Full-Text Articles in Life Sciences

Pharmacometabolomics Profiling Of Preterm Infants Validates Patterns Of Metabolism Associated With Response To Dexamethasone Treatment For Bronchopulmonary Dysplasia., Bradley Stockard, Cheri Gauldin, William E. Truog, Tamorah Lewis Jun 2022

Pharmacometabolomics Profiling Of Preterm Infants Validates Patterns Of Metabolism Associated With Response To Dexamethasone Treatment For Bronchopulmonary Dysplasia., Bradley Stockard, Cheri Gauldin, William E. Truog, Tamorah Lewis

Manuscripts, Articles, Book Chapters and Other Papers

Bronchopulmonary dysplasia (BPD) is one of the most common health complications of premature birth. Corticosteroids are commonly used for treatment of BPD, but their use is challenging due to variability in treatment response. Previous pharmacometabolomics study has established patterns of metabolite levels with response to dexamethasone. We obtained additional patient samples for metabolomics analysis to find associations between the metabolome and dexamethasone response in a validation cohort. A total of 14 infants provided 15 plasma and 12 urine samples. The measure of treatment response was the calculated change in respiratory severity score (deltaRSS) from pre-to-post treatment. Each metabolite was assessed …


Pharmacometabolomics Profiling Of Preterm Infants Validates Patterns Of Metabolism Associated With Response To Dexamethasone Treatment For Bronchopulmonary Dysplasia, Bradley C. Stockard May 2022

Pharmacometabolomics Profiling Of Preterm Infants Validates Patterns Of Metabolism Associated With Response To Dexamethasone Treatment For Bronchopulmonary Dysplasia, Bradley C. Stockard

Research Days

Background: Bronchopulmonary dysplasia (BPD) is one of the most common health complications of premature birth. Corticosteroids are commonly used for treatment of BPD, but their use is challenging due to variability in treatment response.

Objectives/Goal: Previous pharmacometabolomics study has established patterns of metabolite levels with response to dexamethasone. We obtained additional patient samples for metabolomics analysis to find associations between the metabolome and dexamethasone response in a validation cohort.

Methods/Design: 14 infants provided 15 plasma and 12 urine samples. The measure of treatment response was the calculated change in respiratory severity score (deltaRSS) from pre-to-post treatment. Each metabolite was assessed …


Case Report: Pharmacogenetics Applied To Precision Psychiatry Could Explain The Outcome Of A Patient With A New Cyp2d6 Genotype, Elena Marcos-Vadillo, Lorena Carrascal-Laso, Ignacio Ramos-Gallego, Andrea Gaedigk, Belén García-Berrocal, Eduardo Mayor-Toranzo, Alfonso Sevillano-Jiménez, Almudena Sánchez, María Isidoro-García, Manuel Franco-Martín Feb 2022

Case Report: Pharmacogenetics Applied To Precision Psychiatry Could Explain The Outcome Of A Patient With A New Cyp2d6 Genotype, Elena Marcos-Vadillo, Lorena Carrascal-Laso, Ignacio Ramos-Gallego, Andrea Gaedigk, Belén García-Berrocal, Eduardo Mayor-Toranzo, Alfonso Sevillano-Jiménez, Almudena Sánchez, María Isidoro-García, Manuel Franco-Martín

Manuscripts, Articles, Book Chapters and Other Papers

Precision medicine applied to psychiatry provides new insight into the promising field of precision psychiatry. Psychotic disorders are heterogeneous, complex, chronic, and severe mental disorders. Not only does the prognosis and the course of the disease vary among patients suffering from psychotic disorders, but the treatment response varies as well. Although antipsychotic drugs are the cornerstone of the treatment of schizophrenia, many patients only partially respond to these drugs. Furthermore, patients often experience adverse events which can lead to poor treatment adherence. Interindividual variability in drug response could be related to age, gender, ethnicity, lifestyle factors, pharmacological interactions, obesity, and …


Ten Years Of Experience Support Pharmacogenetic Testing To Guide Individualized Drug Therapy., María Celsa Peña-Martín, Belén García-Berrocal, Almudena Sánchez-Martín, Elena Marcos-Vadillo, María Jesús García-Salgado, Santiago Sánchez, Carolina Lorenzo, David González-Parra, Francisco Sans, Manuel Franco, Andrea Gaedigk, María José Mateos-Sexmero, Catalina Sanz, María Isidoro-García Jan 2022

Ten Years Of Experience Support Pharmacogenetic Testing To Guide Individualized Drug Therapy., María Celsa Peña-Martín, Belén García-Berrocal, Almudena Sánchez-Martín, Elena Marcos-Vadillo, María Jesús García-Salgado, Santiago Sánchez, Carolina Lorenzo, David González-Parra, Francisco Sans, Manuel Franco, Andrea Gaedigk, María José Mateos-Sexmero, Catalina Sanz, María Isidoro-García

Manuscripts, Articles, Book Chapters and Other Papers

Precision medicine utilizing the genetic information of genes involved in the metabolism and disposition of drugs can not only improve drug efficacy but also prevent or minimize adverse events. Polypharmacy is common among multimorbid patients and is associated with increased adverse events. One of the main objectives in health care is safe and efficacious drug therapy, which is directly correlated to the individual response to treatment. Precision medicine can increase drug safety in many scenarios, including polypharmacy. In this report, we share our experience utilizing precision medicine over the past ten years. Based on our experience using pharmacogenetic (PGx)-informed prescribing, …